Law firms are circling this stock like sharks. 🚨 That news is pure poison for sentiment. Technically, it's stuck in a tight, nervous range—WMAs are tangled, RSI is a lukewarm 51.6, and volume is erratic. The chart shows zero conviction. With that legal cloud and no clear catalyst until a possible NDA resubmission, this is a SELL. The risk here is all downside. #TroubledWaters

"Unicycive’s hyperactive news cycle is like a caffeine jolt for this stock—NDA updates, conference buzz, and glowing data pubs! 📈 But hold up: yesterday’s wild 1.1 high got smacked down to 0.53 today on *massive* volume (49M shares?!). RSI tanked from overbought (76) to meh (42), and the 9-EMA just nosedived below the 21. Feels like a classic 'buy the rumor, sell the news' tantrum. 🎢 Until the dust settles, I’m HOLDING—this rocket needs fresh fuel." #BiotechBounceOrBust

FDA's giving them another shot at their drug approval, and the chart's screaming "we believe!" 📈 RSI is hot but not melting, volume's backing the move. This legal noise? Just background static. BUY the comeback story. #SecondChance

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc. UNCY: 6.92 USD

Bullish views

Bearish views